Ad is loading...
MGTX
Price
$5.92
Change
+$0.10 (+1.72%)
Updated
Nov 21 closing price
110 days until earnings call
SCPH
Price
$3.46
Change
+$0.10 (+2.98%)
Updated
Nov 21 closing price
117 days until earnings call
Ad is loading...

MGTX vs SCPH

Header iconMGTX vs SCPH Comparison
Open Charts MGTX vs SCPHBanner chart's image
MeiraGTx Holdings
Price$5.92
Change+$0.10 (+1.72%)
Volume$155.56K
CapitalizationN/A
scPharmaceuticals
Price$3.46
Change+$0.10 (+2.98%)
Volume$267.73K
CapitalizationN/A
MGTX vs SCPH Comparison Chart
Loading...
MGTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MGTX vs. SCPH commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGTX is a StrongSell and SCPH is a StrongBuy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (MGTX: $5.92 vs. SCPH: $3.46)
Brand notoriety: MGTX and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MGTX: 49% vs. SCPH: 70%
Market capitalization -- MGTX: $462.67M vs. SCPH: $173.14M
MGTX [@Biotechnology] is valued at $462.67M. SCPH’s [@Biotechnology] market capitalization is $173.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MGTX’s FA Score shows that 0 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • MGTX’s FA Score: 0 green, 5 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, MGTX is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MGTX’s TA Score shows that 4 TA indicator(s) are bullish while SCPH’s TA Score has 5 bullish TA indicator(s).

  • MGTX’s TA Score: 4 bullish, 5 bearish.
  • SCPH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than MGTX.

Price Growth

MGTX (@Biotechnology) experienced а -10.84% price change this week, while SCPH (@Biotechnology) price change was +2.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.

Reported Earning Dates

MGTX is expected to report earnings on Mar 12, 2025.

SCPH is expected to report earnings on Mar 19, 2025.

Industries' Descriptions

@Biotechnology (-3.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MGTX($463M) has a higher market cap than SCPH($173M). MGTX YTD gains are higher at: -15.670 vs. SCPH (-44.817). MGTX has higher annual earnings (EBITDA): -61.2M vs. SCPH (-71.31M). MGTX has more cash in the bank: 123M vs. SCPH (91.5M). SCPH has less debt than MGTX: SCPH (52.5M) vs MGTX (86.7M). SCPH has higher revenues than MGTX: SCPH (30.3M) vs MGTX (13.9M).
MGTXSCPHMGTX / SCPH
Capitalization463M173M268%
EBITDA-61.2M-71.31M86%
Gain YTD-15.670-44.81735%
P/E RatioN/AN/A-
Revenue13.9M30.3M46%
Total Cash123M91.5M134%
Total Debt86.7M52.5M165%
FUNDAMENTALS RATINGS
MGTX vs SCPH: Fundamental Ratings
MGTX
SCPH
OUTLOOK RATING
1..100
8057
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
4487
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MGTX's Valuation (54) in the Biotechnology industry is in the same range as SCPH (55) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew similarly to SCPH’s over the last 12 months.

MGTX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew similarly to SCPH’s over the last 12 months.

MGTX's SMR Rating (98) in the Biotechnology industry is in the same range as SCPH (99) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew similarly to SCPH’s over the last 12 months.

MGTX's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for SCPH (87) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew somewhat faster than SCPH’s over the last 12 months.

MGTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that MGTX’s stock grew similarly to SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MGTXSCPH
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 17 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
MGTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSMCX48.810.86
+1.79%
Congress Small Cap Growth Institutional
FCVAX20.890.33
+1.61%
Fidelity Advisor Small Cap Value A
FLIAX11.220.17
+1.54%
First Sentier American Listed Infras Ins
IBSAX20.830.30
+1.46%
VY® Baron Growth A
INDEX56.820.31
+0.55%
ONEFUND S&P 500®

MGTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGTX has been loosely correlated with NTLA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MGTX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGTX
1D Price
Change %
MGTX100%
+1.72%
NTLA - MGTX
51%
Loosely correlated
+5.18%
BEAM - MGTX
49%
Loosely correlated
-3.72%
EDIT - MGTX
48%
Loosely correlated
-1.66%
ABOS - MGTX
47%
Loosely correlated
-2.53%
ABCL - MGTX
46%
Loosely correlated
+1.87%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with XERS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
+2.98%
XERS - SCPH
45%
Loosely correlated
-0.65%
MGTX - SCPH
44%
Loosely correlated
+1.72%
AURA - SCPH
43%
Loosely correlated
+3.20%
PLRX - SCPH
43%
Loosely correlated
+0.94%
INZY - SCPH
43%
Loosely correlated
-3.58%
More